New syringe design tested for eye injections
NCT ID NCT07550504
First seen Apr 29, 2026 · Last updated May 01, 2026 · Updated 2 times
Summary
This study tested whether doctors could easily use a pre-filled syringe of the drug SB11 (a biosimilar of ranibizumab) to treat certain eye conditions. Thirty participants with age-related macular degeneration, macular edema from retinal vein occlusion, or myopic choroidal neovascularization received one injection. The main goal was to see if doctors could successfully complete all 12 steps needed to prepare and give the injection.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYOPIC CHOROIDAL NEOVASCULARIZATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research site
Krakow, Poland
-
Research site
Olsztyn, Poland
Conditions
Explore the condition pages connected to this study.